Phio Pharmaceuticals Files 8-K
Ticker: PHIO · Form: 8-K · Filed: Dec 19, 2024 · CIK: 1533040
| Field | Detail |
|---|---|
| Company | Phio Pharmaceuticals Corp. (PHIO) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, financial-update
TL;DR
Phio Pharma filed an 8-K on Dec 18, 2024, likely with financial updates. Keep an eye out.
AI Summary
On December 18, 2024, Phio Pharmaceuticals Corp. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This 8-K filing signals that Phio Pharmaceuticals Corp. is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate indication of significant negative or positive events, thus posing a low immediate risk.
Key Players & Entities
- Phio Pharmaceuticals Corp. (company) — Registrant
- December 18, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36304 (identifier) — Commission File Number
- Marlborough, Massachusetts (location) — Principal executive offices
- RXi Pharmaceuticals Corp (company) — Former company name
FAQ
What specific "Other Events" are being reported by Phio Pharmaceuticals Corp. in this 8-K filing?
The provided excerpt of the 8-K filing does not detail the specific "Other Events" being reported, only that this item is included.
What is the significance of the "Financial Statements and Exhibits" being listed as an item in this 8-K?
This indicates that the filing includes or updates financial statements and/or exhibits, which are crucial for investors to assess the company's financial health.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 18, 2024.
What was Phio Pharmaceuticals Corp.'s former name?
Phio Pharmaceuticals Corp.'s former name was RXi Pharmaceuticals Corp.
Where are Phio Pharmaceuticals Corp.'s principal executive offices located?
Phio Pharmaceuticals Corp.'s principal executive offices are located at 11 Apex Drive, Suite 300A, PMB 2006, Marlborough, Massachusetts 01752.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-12-19 08:38:33
Key Financial Figures
- $0.0001 — h registered: Common Stock, par value $0.0001 per share PHIO The Nasdaq Capital M
Filing Documents
- phio_8k.htm (8-K) — 27KB
- phio_ex9901.htm (EX-99.1) — 11KB
- image_001.jpg (GRAPHIC) — 2KB
- 0001683168-24-008833.txt ( ) — 215KB
- phio-20241218.xsd (EX-101.SCH) — 3KB
- phio-20241218_lab.xml (EX-101.LAB) — 33KB
- phio-20241218_pre.xml (EX-101.PRE) — 22KB
- phio_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On December 19, 2024, Phio Pharmaceuticals Corp. (the "Company") issued a press release announcing that a Safety Monitoring Committee reviewed safety data from the second dose cohort treated in the Phase 1b clinical trial with the Company's lead compound PH-762 and recommended the escalation to the next dose concentration. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by the Company on December 19, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHIO PHARMACEUTICALS CORP. Date: December 19, 2024 By: /s/ Robert Bitterman Robert Bitterman President & Chief Executive Officer 3